EMA GMP Guidelines Update 2026-2028
Austin Chuang • April 10, 2026
Prepare for the EMA's new 3-year work plan including updates to Annex 15, Annex 22, and key GMP chapters.
EMA GMP Guidelines Work Plan (2026-2028)
Executive Summary
The European Medicines Agency (EMA) has mapped out its regulatory trajectory for the next three years. Prepared by the GMDP Inspectors Working Group, this comprehensive plan outlines critical revisions to GMP requirements. Focus areas include finalizing guidelines on Artificial Intelligence, Validation, and the Pharmaceutical Quality System by 2026, setting the stage for modernized compliance standards.
Key texts expected by end of 2026 include Chapter 1 (Quality System), Chapter 4 (Documentation), Annex 15 (Qualification and Validation), and the highly anticipated Annex 22 (Artificial Intelligence).
Significant workload continues with finalized revisions targeted for 2028 on Premises (Ch. 3), Production (Ch. 5), Outsourcing (Ch. 7), and specific annexes covering Radiopharmaceuticals and Blood/Plasma products.
Advanced Therapy Medicinal Products (ATMPs) GMP guidelines will undergo rigorous review. Additionally, integration and implementation of the ICH Q12 Lifecycle Management guideline will be clarified this year.
Stay Ahead of Regulatory Changes with PE
Persimmon Engineering (PE) specializes in System Design, Validation, and Regulatory Compliance. Whether navigating the new Annex 22 requirements for AI or updating your qualification strategies for Annex 15, our experts ensure your facilities and processes remain audit-ready.
Consult Our Compliance ExpertsOriginal Source Content
01.04.2026
New EMA GMP Guidelines in the next three Years
The European Medicines Agency (EMA) has published a new version of the '3-year work plan for the Inspectors Working Group' covering the period from January 2026 to December 2028. The plan is drawn up by the GMDP Inspectors Working Group (GMDP IWG).
It also includes, in some cases, revised timelines for the revision of GMP requirements.
The following chapters and annexes are to be finalised by the end of 2026 ("provide the European Commission with a final text"):
- Chapter 1 (Pharmaceutical Quality System)
- Chapter 4 (Documentation)
- Annex 15 Qualification and Validation
- Annex 22 Artificial Intelligence
At least a review is to be carried out for the "Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products".
The procedure for implementing the ICH Q12 guideline "Lifecycle Management" is also to be clarified by the end of the year.
A great deal of work is then planned for the next two years, and the revisions to the following chapters and annexes are to be finalised by the end of 2028:
- Chapter 3 (Premises and Equipment)
- Chapter 5 (Production)
- Chapter 7 (Outsourced Activities)
- Chapter 9 (Self-Inspection)
- Annex 3 Manufacture of Radiopharmaceuticals
- Annex 6 Manufacture of Medicinal Gases
- Annex 14 Manufacture of Medicinal Products Derived from Human Blood or Plasma
Further details can be found in the current document The 3-year work plan for the Inspectors Working Group.
Source: https://www.gmp-compliance.org/gmp-news/new-ema-gmp-guidelines-in-the-next-three-years
Primary Keywords: EMA GMP Guidelines, GMDP IWG, Annex 15 Validation, Annex 22 AI
Targeted Phrases: EMA 3-year work plan for GMP inspectors, revision of GMP requirements 2026, Annex 22 Artificial Intelligence guidelines
Hashtags: #EMAGMP #RegulatoryCompliance #PharmaValidation #Annex15 #Annex22